At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Moderna, Danaher, Gilead Sciences, AbbVie, and Roivant Sciences are the five Biotech stocks to watch today, according to MarketBeat

Roivant Sciences (NASDAQ:ROIV) reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflammatory eye disease that can result in vision loss. Matt Gline, Roivant’s chief execut

For patients with macular edema, 42% of eyes on brepocitinib had resolution versus 4.8% on placebo; Priovant plans a supplemental filing in the first half of 2027.

At $33.53 per share, the October 16 tax withholding followed satisfaction of performance and service conditions. More awards will settle in installments.

Matthew Gline held 16,549,136 shares afterward. Shares issued from the settlement, excluding those withheld for taxes, have a two-year holding period.

Eric Venker lists October 20, 2026, as the approximate sale date under a trading plan adopted June 30, with Rockefeller Financial LLC as broker.

Get the live share price of Roivant Sciences Ltd (ROIV), including intraday charts, historical performance, key financials, and market updates. Track the latest US stock market activity.